BJ ENT URBAN (03718.HK): Wins Dali County Sanitation Project with Estimated Contract Value of RMB 208.08 Million
NewTimeSpace News: On 13 November 2026, BJ ENT URBAN (03718.HK) said in a voluntary announcement that its wholly-owned subsidiary Beijing Enterprises Urban Environmental Services Group Co., Ltd. won the tender for the Dali County integrated urban and rural sanitation service project, following a tender process run by local authorities of Dali County, Weinan City, Shaanxi Province, with 12 November 2026 as the award date.
The project carries an estimated total contract value of RMB 208.08 million and estimated annual revenue of RMB 69.36 million, with a contract period of three years on a one-year renewal basis, under which the following year's contract is signed once renewal conditions are met.
The scope covers roads, parks and squares, back streets and the Tongzhou new district in the county seat, plus street, township, village road and village cleaning services in 17 townships and sub-districts. It also includes collection and transport of household waste in the county seat, the installation and operation of 94 rural household waste collection points, public toilet maintenance, construction and operation of a smart city management platform and the deployment of intelligent equipment and new energy sanitation vehicles, together with emergency support and other sanitation services.
The Group obtained the tender result from the relevant local government platform and has not entered into any formal contract for the tender, the announcement said, adding that the actual contract value and total revenue may differ from the announcement due to unexpected changes in market conditions and other factors, and that no profit forecast or estimate for the tender was made.
- AB&B BIO-TECH-B (02627.HK): Adsorbed Tetanus Vaccine Wins CDE IND Clearance
- CLOUD FACTORY (02512.HK): RMB241m Server Purchases, Both Discloseable
- BOCOM INTL (03329.HK): Buys US$12m Standard Chartered Notes for HK$93.6m
- LINGBAO GOLD (03330.HK): Royalty on Remaining 50%-1 Stake Capped at A$244m
- HENGRUI PHARMA (01276.HK): Six Drugs Cleared for Clinical Trials, Including Two ADCs